Tuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?

Adriana Rojas-Villarraga, Carlos Andrés Agudelo, Ricardo Pineda-Tamayo, Alvaro Porras, Gustavo Matute, Juan Manuel Anaya

Resultado de la investigación: Contribución a RevistaRevisión Literaria

7 Citas (Scopus)

Resumen

Tumor necrosis factor alpha antagonists (TNFA) are biological agents to treat chronic inflammatory and autoimmune diseases. However, their use is associated with an increased rate of tuberculosis, endemic mycoses, and intracellular bacterial infections. Since tuberculosis is moderately to highly endemic in Colombia, the risk of these infections in patients treated with TNFAs may be higher than previously reported in Colombia. Recently, four patients have developed tuberculosis during TNFA therapy. Tuberculosis appeared between 3 to 24 months after initiation of TFNA therapy and was independent of previous tuberculin skin test status. A review of the relevant literature and recommendations are presented as guides for surveillance and prophylaxis on a country-wide basis.
Idioma originalEnglish (US)
Páginas (desde-hasta)159-171
Número de páginas13
PublicaciónBiomedica
EstadoPublished - abr 1 2007

Huella dactilar

Tuberculosis
Tumor Necrosis Factor-alpha
Colombia
Tuberculin
Biological Factors
Bacterial Infections and Mycoses
Skin
Tuberculin Test
Skin Tests
Autoimmune Diseases
Chronic Disease
Therapeutics
Infection

Citar esto

Rojas-Villarraga, Adriana ; Agudelo, Carlos Andrés ; Pineda-Tamayo, Ricardo ; Porras, Alvaro ; Matute, Gustavo ; Anaya, Juan Manuel. / Tuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?. En: Biomedica. 2007 ; pp. 159-171.
@article{aa373f1bad3147d6a7ff6d80c879735d,
title = "Tuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?",
abstract = "Tumor necrosis factor alpha antagonists (TNFA) are biological agents to treat chronic inflammatory and autoimmune diseases. However, their use is associated with an increased rate of tuberculosis, endemic mycoses, and intracellular bacterial infections. Since tuberculosis is moderately to highly endemic in Colombia, the risk of these infections in patients treated with TNFAs may be higher than previously reported in Colombia. Recently, four patients have developed tuberculosis during TNFA therapy. Tuberculosis appeared between 3 to 24 months after initiation of TFNA therapy and was independent of previous tuberculin skin test status. A review of the relevant literature and recommendations are presented as guides for surveillance and prophylaxis on a country-wide basis.",
author = "Adriana Rojas-Villarraga and Agudelo, {Carlos Andr{\'e}s} and Ricardo Pineda-Tamayo and Alvaro Porras and Gustavo Matute and Anaya, {Juan Manuel}",
year = "2007",
month = "4",
day = "1",
language = "English (US)",
pages = "159--171",
journal = "Biomedica",
issn = "0120-4157",
publisher = "Instituto Nacional de Salud",

}

Tuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile? / Rojas-Villarraga, Adriana; Agudelo, Carlos Andrés; Pineda-Tamayo, Ricardo; Porras, Alvaro; Matute, Gustavo; Anaya, Juan Manuel.

En: Biomedica, 01.04.2007, p. 159-171.

Resultado de la investigación: Contribución a RevistaRevisión Literaria

TY - JOUR

T1 - Tuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?

AU - Rojas-Villarraga, Adriana

AU - Agudelo, Carlos Andrés

AU - Pineda-Tamayo, Ricardo

AU - Porras, Alvaro

AU - Matute, Gustavo

AU - Anaya, Juan Manuel

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Tumor necrosis factor alpha antagonists (TNFA) are biological agents to treat chronic inflammatory and autoimmune diseases. However, their use is associated with an increased rate of tuberculosis, endemic mycoses, and intracellular bacterial infections. Since tuberculosis is moderately to highly endemic in Colombia, the risk of these infections in patients treated with TNFAs may be higher than previously reported in Colombia. Recently, four patients have developed tuberculosis during TNFA therapy. Tuberculosis appeared between 3 to 24 months after initiation of TFNA therapy and was independent of previous tuberculin skin test status. A review of the relevant literature and recommendations are presented as guides for surveillance and prophylaxis on a country-wide basis.

AB - Tumor necrosis factor alpha antagonists (TNFA) are biological agents to treat chronic inflammatory and autoimmune diseases. However, their use is associated with an increased rate of tuberculosis, endemic mycoses, and intracellular bacterial infections. Since tuberculosis is moderately to highly endemic in Colombia, the risk of these infections in patients treated with TNFAs may be higher than previously reported in Colombia. Recently, four patients have developed tuberculosis during TNFA therapy. Tuberculosis appeared between 3 to 24 months after initiation of TFNA therapy and was independent of previous tuberculin skin test status. A review of the relevant literature and recommendations are presented as guides for surveillance and prophylaxis on a country-wide basis.

M3 - Literature review

SP - 159

EP - 171

JO - Biomedica

JF - Biomedica

SN - 0120-4157

ER -